Wednesday 20 May 2026

One To Watch

iTeos Therapeutics

A clinical-stage biopharmaceutical company developing new generation, highly differentiated immuno-oncology therapeutics.

Company Overview

Want to Update your Company's Profile?


Latest iTeos Therapeutics News

iTeos Therapeutics accepts takeover bid from Concentra
22 July 2025
iTeos to shut down operations after TIGIT setback and GSK exit
29 May 2025
The week in pharma: action, reaction and insight – week to May 16
18 May 2025
iTeos and GSK to drop belrestotug + dostarlimab collaboration
13 May 2025
More iTeos Therapeutics news >


Today's issue

Scene set for Scenic to take ‘top-notch science’ into the clinic
Biotechnology
Scene set for Scenic to take ‘top-notch science’ into the clinic
20 May 2026
Pharmaceutical
US State price-setting boards create more questions than answers
20 May 2026
Pharmaceutical
Chiesi appoints Maria Paola Chiesi as first female chair
20 May 2026
Biotechnology
UK launches national framework to strengthen advanced therapy clinical trials
20 May 2026
Pharmaceutical
Remepy posts strong Phase IIa results for Hybridopa
20 May 2026
Pharmaceutical
Pfizer advances pediatric pneumococcal vaccine program
20 May 2026
Biosimilars
MS Pharma wins investment from Olayan Financing
20 May 2026




Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze